

Table S1. Bivalent-vaccinated HCW and BA.2.86/JN.1-wave first responder cohorts

	Bivalent Health Care Workers (n=10)	BA.2.86/JN.1 Wave Patients (n=7)
Age in Years at Sample Collection [Median (Range)]	37 (27-46)	51 (35-77)
Gender [n (% of Total)]		
Male	5 (50%)	3 (42.9%)
Female	5 (50%)	4 (57.1%)
Sample Collection Window	Dec. 2022- Jan.2023	Nov. 2023-Feb.2024
Vaccine status [n (% of Total)]		
2-dose Moderna	NA	2 (28.6%)
3-dose Moderna	NA	1 (14.3%)
4-dose Moderna	NA	1 (14.3%)
1-dose Moderna +1-dose Pfizer bivalent	NA	1 (14.3%)
2-dose Pfizer +1-dose Pfizer bivalent	1 (10%)	NA
3-dose Pfizer +1-dose Moderna bivalent	NA	1 (14.3%)
3-dose Pfizer +1-dose Pfizer bivalent	3 (30%)	NA
3-dose Pfizer +1-dose Moderna	1 (10%)	NA
3-dose Moderna +1-dose Moderna bivalent	4 (40%)	1 (14.3%)
2-dose Moderna +1 Pfizer +1-dose Pfizer bivalent	1 (10%)	NA
Days from last vaccination	NA	434 (34-892)
Days post the bivalent dose for recipients	66 (23-108)	NA
COVID-19 positive [n (% of Total)]	8 (80%)	7 (100%)
Days before sample collection [(Median Range)]	276.5 (182-994)	7 (3-10)
Infected Variants		
JN.1/BA.2.86	NA	2 (28.6%)
Undetermined	NA	5 (71.4%)

Summary of the demographic information for two cohorts used for neutralization experiments depicted in Figure 2. “NA” means the category is not applicable to the cohort.